Valeo Financial Advisors LLC Sells 1,372 Shares of Amgen Inc. $AMGN

Valeo Financial Advisors LLC lessened its position in Amgen Inc. (NASDAQ:AMGN) by 7.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,375 shares of the medical research company’s stock after selling 1,372 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Amgen were worth $6,292,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. lifted its position in Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC bought a new position in shares of Amgen in the 4th quarter valued at about $1,669,000. Adell Harriman & Carpenter Inc. grew its holdings in shares of Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Amgen in the fourth quarter valued at about $22,441,000. Finally, Sigma Planning Corp increased its position in shares of Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after acquiring an additional 3,488 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on AMGN. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Mizuho boosted their price target on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. TD Cowen upped their price objective on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Guggenheim increased their price objective on Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $370.07.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Trading Up 1.5%

Shares of NASDAQ:AMGN opened at $410.95 on Friday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $418.40. The company has a market capitalization of $222.17 billion, a P/E ratio of 25.54, a price-to-earnings-growth ratio of 3.83 and a beta of 0.41. The company has a 50-day simple moving average of $362.77 and a 200 day simple moving average of $356.24. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.01 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.